Malta - inglés - Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - phenytoin sodium - hard capsule - phenytoin sodium 50 mg - antiepileptics

Malta - inglés - Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - latanoprost - eye drops, solution - latanoprost 50 µg/ml - ophthalmologicals

Malta - inglés - Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - solution for injection/infusion - phenytoin sodium 50 mg/ml - antiepileptics

Malta - inglés - Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - oral suspension - phenytoin 30 mg/5ml - antiepileptics

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 500 mg - tablet, uncoated - excipient ingredients: gelatin; sodium benzoate; purified water; docusate sodium; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; maize starch; isopropyl alcohol; macrogol 400 - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone; ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone; ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone - capsule - active: ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch - ziprasidone is also indicated as a monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar 1 disorder.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 22.652mg equivalent to 20 mg ziprasidone - capsule - 20 mg - active: ziprasidone hydrochloride monohydrate 22.652mg equivalent to 20 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone - capsule - 40 mg - active: ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone - capsule - 60 mg - active: ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone - capsule - 80 mg - active: ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.